STAT

OCTOBER 20, 2023

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

Compounding 304

Compounding Chemotherapy Hospitals Drug Development 304

STAT

OCTOBER 23, 2023

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

Chemotherapy 295

Chemotherapy Drug Development 295

STAT

JULY 3, 2023

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.  

Chemotherapy 252

Chemotherapy Drug Development 252

European Pharmaceutical Review

JULY 4, 2023

As drug development professionals know, global health crises like the COVID-19 pandemic provide the public with valuable insights into how clinical research and regulatory processes work.

Drug Development 98

Drug Development Communication Dosage Chemotherapy 98

Pharmaceutical Technology

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin.

Chemotherapy 98

Chemotherapy Drug Development 98

Express Pharma

APRIL 3, 2023

Neha Myneni, Pharma Analyst at GlobalData, comments, “As the clinical benefit derived from ADCs as monotherapy is limited due to the emergence of resistance mechanisms, several companies currently focus on developing ADC combinations with other anti-cancer drugs like chemotherapy, molecularly targeted agents, and immunotherapies.”

Chemotherapy 98

Chemotherapy Compounding Drug Development 98

pharmaphorum

FEBRUARY 11, 2022

” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.

Chemotherapy 112

Chemotherapy Drug Development 112

pharmaphorum

APRIL 27, 2021

On Wednesday (28 April), the focus will shift to Keytruda and Tecentriq as first-line treatments for UC patients unable to be treated with cisplatin-containing chemotherapy – which got the go-ahead in 2017 and 2018, respectively.

Chemotherapy 90

Chemotherapy Documentation Drug Development 90

pharmaphorum

DECEMBER 9, 2022

AZ estimates that approximately 70% of breast cancer tumours are considered HR-positive and HER2-low or negative and, if first-line endocrine therapies fail, their only option currently is single-agent chemotherapy.

Chemotherapy 98

Chemotherapy Drug Development 98

pharmaphorum

JUNE 8, 2021

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6% Mei says that oncology is one of the key region-specific unmet medical needs Antengene is hoping to address with innovative drugs.

Chemotherapy 106

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 106

European Pharmaceutical Review

MARCH 15, 2023

The discovery of MEN1 mutation as a resistance mechanism indicates that new drugs that targeting menin or other chromatin-associated proteins could prevent or delay revumenib resistance or treat patients who have become resistant to the drug.

Chemotherapy 105

Chemotherapy Packaging Drug Development 105

pharmaphorum

APRIL 8, 2022

In trials, Trodelvy significantly improved both progression free survival (PFS) and overall survival (OS) in adults with locally advanced or metastatic TNBC without brain metastases – who had received at least two prior chemotherapy regimens including a taxane – compared with a range of single-agent chemotherapies.

Chemotherapy 59

Chemotherapy Drug Development 59

pharmaphorum

DECEMBER 5, 2022

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.

Chemotherapy 59

Chemotherapy Labelling Compounding Drug Development 59

European Pharmaceutical Review

AUGUST 12, 2024

Progress in immunotherapy drug development In June, the US Food and Drug Administration (FDA) authorised an immunotherapy combination to treat endometrial cancer. The deal is anticipated to be finalised in Q3 of 2024.

Research Laboratories 59

Research Laboratories Chemotherapy Drug Development 59

pharmaphorum

SEPTEMBER 29, 2020

As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

Drug Development 132

Drug Development Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 132

pharmaphorum

JULY 22, 2021

The green light for Pemazyre (pemigatinib) has been hailed by cholangiocarcinoma charity AMMF, which said it was a “major milestone” in the fight against the “Cinderella” cancer, which for years has been overlooked by drug developers.

Chemotherapy 59

Chemotherapy Labelling Drug Development 59

European Pharmaceutical Review

DECEMBER 28, 2023

As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients. Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

pharmaphorum

JANUARY 5, 2021

Roche’s drug is already FDA-approved as a monotherapy and in combination with Avastin (bevacizumab) and chemotherapy for previously-untreated NSCLC with high PD-L1 expression. Meanwhile, drugs targeting TIM-3, LAG3, VISTA and STING also coming through development.

Chemotherapy 52

Chemotherapy Immunity Immunization Labelling 52

pharmaphorum

SEPTEMBER 28, 2022

The time places exa-cel in pole position to become the first drug developed based on CRISPR/Cas9 gene-editing technology to reach the market.

Chemotherapy 59

Chemotherapy Drug Development 59

pharmaphorum

MARCH 30, 2021

The filing includes the UNITY-CLL phase 3 trial, a randomised study comparing the U2 combination therapy with an active control arm in which patients received Roche’s Gazyvaro plus chlorambucil chemotherapy in both treatment-naïve patients and those with relapsed/refractory disease.

Chemotherapy 52

Chemotherapy Drug Development 52

pharmaphorum

JUNE 12, 2022

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease.

Chemotherapy 59

Chemotherapy Drug Development 59

pharmaphorum

MAY 27, 2022

Almost all of the patients had been previously treated with chemotherapy and immunotherapy. KRAS mutations are seen in around a quarter of NSCLC tumours, with KRAS G12C mutations in particular found in around 13% of cases, but the target defied drug developers for decades.

Chemotherapy 52

Chemotherapy Drug Development 52

pharmaphorum

APRIL 23, 2021

After a string of disappointments including the failure of bintrafusp alfa , a drug developed with Germany’s Merck KGaA in lung cancer, any approval is welcome news.

Chemotherapy 52

Chemotherapy Labelling Drug Development 52

Pharmaceutical Technology

JUNE 10, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

FEBRUARY 24, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Compounding Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 19, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Diabetes Drug Development 40

European Pharmaceutical Review

AUGUST 31, 2023

By reaching cancer cells that have already spread throughout the body, a targeted radiopharmaceutical treatment offers an alternative for patients with advanced cancer when standard lines of treatment, such as chemotherapy, have failed. To address these challenges, radiopharmaceutical companies have developed a variety of approaches.

Hospitals 97

Hospitals Drug Development Chemotherapy 97

Pharmaceutical Technology

FEBRUARY 24, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Immunity Immunization Hospitals 40

pharmaphorum

JUNE 23, 2021

Savolitinib will be sold as Orpathys for the treatment of NSCLC patients whose tumours have MET exon 14 skipping mutations who have previously had systemic treatment or are unable to receive chemotherapy. JW’s relmacabtagene autoleucel is currently under review by the NMPA for follicular lymphoma.

Chemotherapy 52

Chemotherapy Drug Development 52

Pharmaceutical Technology

AUGUST 12, 2022

The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. CAR-T cells are an exciting development in this area because, prior to their development, the prognosis for these R/R DLBCL patients was very poor, with no other effective treatment options.

Immunity 52

Immunity Immunization Chemotherapy Compounding 52

pharmaphorum

JANUARY 26, 2022

It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.

Adverse Reactions 40

Adverse Reactions Chemotherapy Immunity Immunization 40

Pharmaceutical Technology

FEBRUARY 13, 2023

Surprisingly, ARV-471 has progressed to Phase III to be evaluated in a less heavily pretreated population where all patients have received CDK4/6 inhibitors, but unlike the Phase II, patients who have received Faslodex or chemotherapy for advanced disease will be excluded.

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

pharmaphorum

APRIL 20, 2022

This would go some way to removing the damage that chemotherapy can do to healthy cells. Distinct from the CRISPR-Cas9 system, the spokesperson added is that the development time of CRISPR-Cas3 assets can be advanced “in half the time and at a fraction of the cost of traditional drug development.”. The pipeline.

Chemotherapy 52

Chemotherapy Immunity Immunization Drug Development 52

STAT

SEPTEMBER 14, 2024

  The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal. Retifanlimab was developed by Incyte and is approved as Zynyz in Merkel cell carcinoma.

Chemotherapy 304

Chemotherapy Drug Development 304

STAT

OCTOBER 21, 2023

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The standard treatment after surgery for these patients is chemotherapy.

Chemotherapy 353

Chemotherapy Drug Development 353

European Pharmaceutical Review

JULY 5, 2022

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.

Chemotherapy 104

Chemotherapy Dosage Labelling Compounding 104